Zealand informs of new data on iGlarLixi and proprietary preclinical peptide drug candidates to be presented at the 76th Annual ...
First time presentations at a scientific congress of results from the two pivotal Phase III trials, LixiLan-L and LixiLan-O, with iGlarLixi Presentations in two oral sessions on Sunday, 12 June 2016 COPENHAGEN, Denmark, June 8, 2016 (GLOBE NEWSWIRE) -- …